Institution:
A new family of molecules against a novel therapeutic target which is overexpressed in HNSCC and related with the resistance acquisition developed by HNSCC patients after chemotherapy.
TspanCure
Tackling cancer heterogeneity: a breakthrough in overcoming chemoresistant tumors First-in-class drugs against a new therapeutic target whose overexpression is involved in the malignancy of very specific cancer types, including HNSCC, pancreatic, breast, among others.
Research Group:
Biomedical Research in Cancer Stem Cells
Researcher/s:
Dr. Matilde E. LLeonart, Dr. Gerard Pujadas, Dr. Amadeu Llebaria
Description:
Aplication areas:
New therapy for HNSCC and other types of cancer such as pancreatic and breast, among others.
Target market:
Big companies and start-ups developing treatments against HNSCC.
Technology Readiness Level (1-9): 3
More information
if you want to know more about this project do not hesitate to contact us